Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the three and nine months ended September 30, 2025 San Diego, CA – November 6, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical- stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and nine months ended September 30, 2025. Corporate Highlights "The outstanding PRIME data and subsequent financing vali ...

SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and nine months ended September 30, 2025. Corporate Highlights Announced Groundbreaking Top-line Results from PRIME Clinical Study Received gross proceeds of $9.6 million from warrant inducement in September 2025 "The out ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 84-3898466 | | --- | --- | | ( State or other jurisdicti ...

SAN DIEGO, CA / ACCESS Newswire / October 15, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced that the Company as a result of insufficient shares present it has adjourned its 2025 Special Meeting of Stockholders (the "Special Meeting") originally convened on October 15, 2025 to allow additional time for stockholders to vote on the proposals described in the Company's proxy materials ...

SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,355,000 shares of common stock, issued by the Company on May 29, 2025 (the "Existing Warrants"), at the existing exercise price of $2.20 per share. The shar ...

- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - Data discussion webcast/conference call will be held at 8:30 am Eastern Time SAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, will host a corporate update ...

SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th webcast at 8:30 am Eastern Time, which can be accessed here or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use the participant access code 289672. We look forward to reviewing the data with you tomorrow mornin ...

Exhibit 99.1 About Gemini Gemini is an intravenously administered, proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD ®) that reduces the damage associated with inflammation by reprogramming the innate immune system to respond to stress (trauma, infection, etc.) in an attenuated manner. Gemini is being developed for multiple indications including as a pretreatment to prevent or reduce the severity and duration of acute kidney injury (GEMINI-AKI program), and as pretreatment to prevent or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 84-3898466 | | --- | --- | | ( State or other jurisdiction of ...

Exhibit 99.1 Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 San Diego, CA – May 8, 2025 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended March 31, 2025 financial results. Corporate Highlights "While we continue to expand the pipeline here at Revelation, we are excited to continue our coll ...